ThursdayMay 09, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per…

Continue Reading

TuesdayMay 07, 2024 11:15 am

Golden Triangle Ventures Inc. (GTVH) New Acquisition Takes Lavish Division One Step Closer to Development of Premier Music, Art Destination

More than half of Americans have attended a music festival, indicating lucrative potential for music and art destinations GTVH recently closed on the acquisition of ABI Create, a premier event-management and production company With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever With Coachella still fresh in music lovers’ memories, it’s only natural to look at what other amazing music festivals might be looming in the future. Destino Ranch comes to mind. A new project focused on becoming an international destination where nature and technology combine to create unforgettable…

Continue Reading

TuesdayMay 07, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024 GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings…

Continue Reading

MondayApr 22, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval

Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful and expensive injection, offering a major opportunity for Lexaria’s oral delivery platform This approval sets the company up for dosing within 30 days or less, with tentative study completion dates for this summer The study will comprise two study arms, the second study arm will investigate whether Lexaria’s patented DehydraTECH(TM)-enhanced semaglutide can effectively…

Continue Reading

ThursdayApr 18, 2024 9:45 am

Software Effective Solutions Corp. (SFWJ) Subsidiary Inks Major Deal with Danziger Colombia

New three-year agreement between SFWJ’s Eko2o and Danziger Colombia reflects both companies’ commitment to sustainable, innovative agriculture practices The collaboration is projected to generate $2.5–$3 million in revenue over the next three years Eko2o will provide greenhouse infrastructure services, irrigation products and technology to Danziger’s flower operations in Colombia Agriculture can have a significant impact on the environment, and an increasing number of companies are working to ensure their agricultural practices are sustainable. Software Effective Solutions (OTC: SFWJ) is among that group, with its majority-controlled, Colombia-based subsidiary Eko2o S.A.S entering a major multiyear contract with Danziger Colombia (https://cnw.fm/apRCJ), the world’s…

Continue Reading

TuesdayApr 16, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans to maintain focus on GLP-1 studies for 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology…

Continue Reading

FridayApr 12, 2024 11:15 am

Golden Triangle Ventures Inc. (GTVH) Announces CEO Interview Series, Partners with Consulting Company on Flagship Destino Ranch Project

CEO interview series provides Golden Triangle with a platform to share its story with an expanded audience Collaboration with Cayenne Consulting will provide key strategic planning and expertise in development of Destino Ranch Destino Ranch aims to redefine luxury entertainment and hospitality experiences As Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, focus on the development of Destino Ranch, a one-of-a-kind immersive entertainment venue, the company is working to increase awareness of the project. As part of these efforts, Golden Triangle is partnering with NowMedia Networks to broadcast 12 weekly interviews with GTVH CEO and president Steffan…

Continue Reading

ThursdayApr 11, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment

Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role in supporting upcoming GLP-1 human clinical studies and overseeing key financial areas of the company The appointment highlights Lexaria’s confidence in its recently confirmed focus on important GLP-1 studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial…

Continue Reading

WednesdayApr 10, 2024 9:00 am

Golden Triangle Ventures Inc. (GTVH) Making Key Progress in Development of Destino Ranch, an Immersive Entertainment Venue

Developed under Lavish Entertainment, a wholly owned subsidiary of GTVH, Destino Ranch will be a one-of-a-kind destination that revolutionizes the concept of an immersive music and art venue. Phase one development begins after the execution of a land-use-and-development agreement outlining exclusive rights to purchase, use and operate the nearly 70-acre property. Additional upgrades on the initial property secured will “dramatically increase speed into the market.” Marco Moreno has been appointed as president of Lavish Entertainment to spearhead the development of Destino Ranch. Mr. Moreno has notable experience in the large-scale event development industry with high-fidelity collaborations through his company ABI…

Continue Reading

MondayMar 25, 2024 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722